Literature DB >> 24426713

Robotic lobectomy for non-small cell lung cancer.

Brian E Louie1.   

Abstract

Over the last 5 years, there has been a tremendous increase in the interest in and use of robotics in thoracic surgery. The focus of this review is on the use of robotics for pulmonary lobectomy, which is being approached with 3 or 4 arm techniques. Early experiences suggest that the learning curve is approximately 20 cases for most surgeons but could be shortened with previous advanced thoracoscopic skills. Robotic lobectomy is feasible and safe in limited reports from experienced centers. Operative and clinical outcomes favor robotic lobectomy over open and appear to be similar to VATS. Limited data on oncologic effectiveness and survival suggest that robotics is similar to VATS. Widespread adoption and integration into practice will require future research efforts to prove oncologic and survival benefits in concert with cost effectiveness evaluation.

Entities:  

Keywords:  Lobectomy; Lung cancer; Robotics; Thoracotomy; VATS

Year:  2013        PMID: 24426713      PMCID: PMC3693146          DOI: 10.1007/s13193-013-0212-4

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  30 in total

1.  Early experience with robotic technology for thoracoscopic surgery.

Authors:  Franca M A Melfi; Gian Franco Menconi; A Massimo Mariani; Carlo Alberto Angeletti
Journal:  Eur J Cardiothorac Surg       Date:  2002-05       Impact factor: 4.191

2.  Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database.

Authors:  Subroto Paul; Nasser K Altorki; Shubin Sheng; Paul C Lee; David H Harpole; Mark W Onaitis; Brendon M Stiles; Jeffrey L Port; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2010-02       Impact factor: 5.209

3.  Cost comparison of robotic, video-assisted thoracic surgery and thoracotomy approaches to pulmonary lobectomy.

Authors:  Bernard J Park; Raja M Flores
Journal:  Thorac Surg Clin       Date:  2008-08       Impact factor: 1.750

Review 4.  The variability of practice in minimally invasive thoracic surgery for pulmonary resections.

Authors:  Gaetano Rocco; Eveline Internullo; Stephen D Cassivi; Dirk Van Raemdonck; Mark K Ferguson
Journal:  Thorac Surg Clin       Date:  2008-08       Impact factor: 1.750

5.  Video-assisted thoracic surgery lobectomy: experience with 1,100 cases.

Authors:  Robert J McKenna; Ward Houck; Clark Beeman Fuller
Journal:  Ann Thorac Surg       Date:  2006-02       Impact factor: 4.330

6.  VATS lobectomy reduces cytokine responses compared with conventional surgery.

Authors:  A P Yim; S Wan; T W Lee; A A Arifi
Journal:  Ann Thorac Surg       Date:  2000-07       Impact factor: 4.330

7.  First experiences with the da Vinci operating robot in thoracic surgery.

Authors:  J Bodner; H Wykypiel; G Wetscher; T Schmid
Journal:  Eur J Cardiothorac Surg       Date:  2004-05       Impact factor: 4.191

8.  Robotic anatomic segmentectomy of the lung: technical aspects and initial results.

Authors:  Alessandro Pardolesi; Bernard Park; Francesco Petrella; Alessandro Borri; Roberto Gasparri; Giulia Veronesi
Journal:  Ann Thorac Surg       Date:  2012-06-28       Impact factor: 4.330

9.  Robot-assisted lobectomy for early-stage lung cancer: report of 100 consecutive cases.

Authors:  Farid Gharagozloo; Marc Margolis; Barbara Tempesta; Eric Strother; Farzad Najam
Journal:  Ann Thorac Surg       Date:  2009-08       Impact factor: 4.330

10.  Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors.

Authors:  Daniel J Boffa; Mark S Allen; Joshua D Grab; Henning A Gaissert; David H Harpole; Cameron D Wright
Journal:  J Thorac Cardiovasc Surg       Date:  2007-12-21       Impact factor: 5.209

View more
  1 in total

1.  Robotic lobectomy: The first Indian report.

Authors:  Arvind Kumar; Belal Bin Asaf; Robert James Cerfolio; Jayshree Sood; Reena Kumar
Journal:  J Minim Access Surg       Date:  2015 Jan-Mar       Impact factor: 1.407

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.